Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Samuel Wickline
University of South Florida, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
AcuPlaq, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Prevention and Treatment of Acute Kidney Injury
Acute kidney injury (AKI) is a frequent clinical problem with an increasing incidence, an unacceptably high mortality rate that has not improved in more than 50 years, and no specific treatment. We have recently proposed and evaluated new image based methods for mapping intrarenal blood volume and PO2 with perfluorocarbon nanoparticle contrast agents employing fluorine (19F) imaging and spectroscopy. We will design and deploy new nanoparticle therapeutic agents that are active against selected inflammatory signaling pathways in unique and effective formulations that provide localized sustained release of agents that may be synergistic in early and advanced AKI, and whose effects on kidney cells can be mapped over time with safe, noninvasive imaging tools.
Filed on February 22, 2018.
Tell us what you know about Samuel Wickline's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Samuel Wickline filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.